AUTHOR=Li Cheng , Wang Ruiliang , Ma Wenchao , Liu Shenghua , Yao Xudong 

TITLE=Do Metastatic Kidney Cancer Patients Benefit From Cytoreductive Nephrectomy? A Real-World Retrospective Study From the SEER Database

JOURNAL=Frontiers in Surgery

VOLUME=8

YEAR=2021

URL=https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2021.716455

DOI=10.3389/fsurg.2021.716455

ISSN=2296-875X

ABSTRACT=<p><bold>Introduction:</bold> The benefit of cytoreductive nephrectomy (CN) for metastatic kidney cancer has been challenged recently. The study aimed to evaluate the prognostic roles of surgical resection of primary tumor site for metastatic kidney cancer under a real-world setting.</p><p><bold>Methods:</bold> The Surveillance, Epidemiology, and End Results (SEER) database (2010–2015) and the overall survival (OS) and cancer-specific survival (CSS) were evaluated using the Cox proportional hazards regression model. One-to-one matching using the propensity score was used to estimate and compare the survival rates.</p><p><bold>Results:</bold> The SEER data contain records of 8,932 patients from 2010 to 2015. The data showed that 61.7% of the patients underwent CN while 38.2% did not receive any surgery. The median survival month for a patient without surgery was 4 months and for a patient with surgery was 19 months. The multivariate analysis showed that surgical resection of the primary tumor site was an independent favorable predictor for both OS and CSS (all <italic>p</italic> &lt; 0.001) in the original and the matching cohort.</p><p><bold>Conclusions:</bold> In the era of target therapy, CN might still be a vital method to treat metastatic kidney cancer.</p>